Overview
- Remedy disclosed on Tuesday that second‑quarter revenue fell 40% year‑over‑year to €10.2 million and first‑half revenue fell 23.1% to €23.3 million, driving a wider operating loss for the quarter.
- The studio said increased Q2 marketing for Control Resonant raised other operating expenses by about €1.7 million and was a key reason for weaker short‑term profitability.
- Control Resonant has passed 1.5 million wishlists, is self‑published and priced at $60, has opened pre‑orders that ranked among the top three PlayStation titles in the US, Germany and Brazil, and will release worldwide on September 24, 2026.
- Some platform decisions — including a PS5‑centred early‑access window and a PS5‑only two‑day Digital Deluxe early access — drew criticism from PC and Xbox players and add commercial risk to the launch.
- Remedy reports Alan Wake 2 has exceeded 3 million lifetime sales, holds about €29.6 million in cash and liquid assets (net cash ~€11.8 million), employs roughly 379 people, and says its full‑year outlook now depends on Resonant’s performance while other projects such as the Max Payne 1&2 remakes and a new title continue in production.